ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)
Sweden · Delayed Price · Currency is SEK 1.360
-0.035 (-2.51%)
Sep 4, 2026, 11:42 AM CET
STO:EXPRS2 Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3.84 | 3.66 | 3.01 | 7.05 | 5.09 | 12.23 |
Other Revenue | 20.41 | 8.55 | 4.81 | 1.75 | 1.06 | 1.5 |
| 24.25 | 12.21 | 7.83 | 8.8 | 6.15 | 13.73 | |
Revenue Growth | 136.71% | 56.00% | -11.07% | 43.07% | -55.21% | -10.04% |
Cost of Revenue | 3.5 | 3.52 | 5.68 | 3.65 | 5.08 | 7.51 |
Gross Profit | 20.75 | 8.69 | 2.14 | 5.15 | 1.07 | 6.22 |
Selling, General & Admin | 39.64 | 41.51 | 41.54 | 58.1 | 56.14 | 35.89 |
Research & Development | 23.73 | 9.98 | 26.66 | 51.42 | 71.32 | 9.82 |
Operating Expenses | 64.59 | 52.96 | 69.84 | 111.12 | 128.68 | 47.51 |
Operating Income | -43.84 | -44.27 | -67.7 | -105.97 | -127.61 | -41.3 |
Interest Expense | -0.16 | -0.45 | -0.73 | -0.5 | -0.87 | - |
Interest & Investment Income | 0.44 | 0.54 | 1.71 | 1.91 | 1.9 | - |
Earnings From Equity Investments | - | - | 22.15 | 4.59 | - | 0.67 |
Other Non Operating Income (Expenses) | - | - | - | - | - | 0.21 |
EBT Excluding Unusual Items | -43.57 | -44.18 | -44.56 | -99.97 | -126.58 | -40.42 |
Other Unusual Items | - | - | - | - | - | -7.1 |
Pretax Income | -43.57 | -44.18 | -44.56 | -99.97 | -126.58 | -47.52 |
Income Tax Expense | -7.65 | -6.09 | -8.53 | -8.57 | -7.98 | -3.59 |
Net Income | -35.91 | -38.09 | -36.04 | -91.4 | -118.61 | -43.93 |
Net Income to Common | -35.91 | -38.09 | -36.04 | -91.4 | -118.61 | -43.93 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 24 | 4 | 2 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 24 | 4 | 2 | 1 | 1 | 1 |
Shares Change | 898.88% | 108.77% | 46.56% | 31.49% | 20.02% | 68.61% |
EPS (Basic) | -1.51 | -10.79 | -21.31 | -79.22 | -135.18 | -60.09 |
EPS (Diluted) | -1.51 | -10.79 | -21.31 | -79.22 | -135.18 | -60.09 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -48.08 | -40.9 | -34.8 | -102.9 | -100 | -46.36 |
Free Cash Flow Per Share | -2.02 | -11.59 | -20.58 | -89.19 | -113.97 | -63.42 |
Gross Margin | 85.57% | 71.16% | 27.40% | 58.55% | 17.38% | 45.28% |
Operating Margin | -180.81% | -362.66% | -865.11% | -1204.28% | -2074.89% | -300.78% |
Profit Margin | -148.11% | -311.99% | -460.55% | -1038.77% | -1928.54% | -319.92% |
Free Cash Flow Margin | -198.30% | -335.09% | -444.70% | -1169.47% | -1625.97% | -337.66% |
EBITDA | -42.62 | -42.81 | -66.06 | -104.37 | -126.35 | -39.8 |
EBITDA Margin | -175.79% | - | - | - | - | -289.87% |
D&A For EBITDA | 1.22 | 1.47 | 1.64 | 1.6 | 1.25 | 1.5 |
EBIT | -43.84 | -44.27 | -67.7 | -105.97 | -127.61 | -41.3 |
EBIT Margin | -180.81% | - | - | - | - | - |
Revenue as Reported | 24.25 | 12.21 | 7.83 | 8.8 | 6.15 | 13.73 |